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This study was designed to evaluate the benefits of neoadjuvant chemotherapy prior to chemoradiation and surgery in patients with
locally advanced rectal cancer. Patients with previously untreated primary rectal cancer, reviewed in a multidisciplinary meeting and
considered to have locally advanced disease on the basis of physical examination and imaging (MRI+CT n¼30, CT alone n¼6),
were recruited. Patients received protracted venous infusion 5-FU (300mgm
 2day
 1 for 12 weeks) with mitomycin C (MMC)
(7mgm
 2 i.v. bolus every 6 weeks). Starting on week 13, 5-FU was reduced to 200mgm
 2day
 1 and concomitant pelvic
radiotherapy 45Gy in 25 fractions was commenced followed by 5.4–9Gy boost to tumour bed. Surgery was planned 6 weeks after
chemoradiation. Postoperatively, patients received 12 weeks of MMC and 5-FU at the same preoperative doses. Between January 99
and August 01, 36 eligible patients were recruited. Median age was 63 years (range¼40–85). Following neoadjuvant chemotherapy,
radiological tumour response was 27.8% (one CR and nine PRs) and no patient had progressive disease. In addition, 65% of patients
had a symptomatic response including improvement in diarrhoea/constipation (59%), reduced rectal bleeding (60%) and diminished
pelvic pain/tenesmus (78%). Following chemoradiation, tumour regression occurred in 80.6% (six CRs and 23 PRs; 95% CI¼64–
91.8%) and only one patient still had an inoperable tumour. R0 resection was achieved in 28 patients (82%). When compared with
initial clinical staging, the pathological downstaging rate in T and/or N stage was 73.5% and pathological CR was found in one patient.
Neoadjuvant systemic chemotherapy as a prelude to synchronous chemoradiation can be administered with negligible risk of disease
progression and produces considerable symptomatic response with associated tumour regression.
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In patients with resectable carcinoma of the rectum, surgery
remains the best option for cure. However, local recurrence
rates of 25–40% have been reported in recent large series of
patients undergoing conventional resection (Havenga et al, 1999;
Nesbakken et al, 2002). Total mesorectal excision (TME), defined
as a sharp dissection under clear vision with the excision of
the rectum and mesorectum within the mesorectal fascia, has been
adopted as the standard technique in rectal cancer by surgeons
in several European countries although there is a lack of
randomised data comparing TME with conventional surgery.
Nevertheless, recurrence rates of o10% (Heald et al, 1998;
Havenga et al, 1999; Nagtegaal et al, 2002; Wibe et al, 2002)
and superior survival (Havenga et al, 1999; Kapiteijn et al,
2002) have been reported with TME. In rectal cancer surgery,
circumferential resection margin (CRM) involvement, defined
as tumour observed p1mm from the resection margin, has
been shown to be an important prognostic factor resulting in
both higher rates of local recurrence (Quirke et al, 1986;
Adam et al, 1994; Birbeck et al, 2002; Nagtegaal et al, 2002; Wibe
et al, 2002) and poor survival (Adam et al, 1994; Birbeck et al,
2002; Wibe et al, 2002) even after TME surgery (Nagtegaal et al,
2002).
Short-course preoperative radiotherapy (5Gy daily for 5 days)
has been shown to have a survival advantage and reduction in local
recurrence compared to surgery alone in operable rectal cancer
(Swedish Rectal Cancer Trial, 1997). Although only one trial has
shown a survival advantage for preoperative radiotherapy (RT), its
results have been found to be representative of that achieved in the
general population (Dahlberg et al, 1999) leading to this approach
being adopted by many oncologists in Europe. However, the value
of preoperative RT in patients undergoing optimised TME surgery
has been questioned and in a large randomised Dutch study of
1805 patients, preoperative RT has been shown to reduce local
recurrence even when TME was used in all patients (Kapiteijn et al,
2001).
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lPreoperative chemoradiation (CRT) has the potential advantages
of eliminating distant micrometastases at an early stage, enhancing
radiosensitivity because of better oxygenated tissue, lowering
incidence of acute toxicity compared with postoperative CRT and
increasing sphincter preservation. The potential disadvantage of
preoperative CRT is overtreatment of patients either because of early
pathological stage (estimated to be 18% in one randomised study
(Sauer et al, 2001)) or presence of occult metastatic disease un-
detected on pretreatment imaging. Preoperative CRT has been used
by many oncologists especially in North America for patients with
clinical T3 disease based on extrapolated benefits from postoperative
CRT and a number of nonrandomised studies demonstrating
significant pathological complete response (pCR) rates and accep-
table acute toxicity profile with the use of preoperative CRT. In
patients with locally advanced, primarily irresectable cancer (i.e. a
cancer where a complete gross surgical clearance is deemed unlikely
to be achieved), preoperative CRT has been used to cause tumour
regression to such an extent that the cancer can be removed radically
with adequate clearance in the resection margin (Videtic et al, 1998;
Chan et al, 2000; Rodel et al, 2000).
The principles on which our study was based were severalfold:
neoadjuvant combination chemotherapy to (1) reduce the bulk of
primary tumour, (2) delay the development of or eliminate
micrometastases and (3) allow immediate commencement of anti-
cancer treatment avoiding potential delay while waiting for definitive
radiotherapy; preoperative synchronous chemoradiation to further
reduce the bulk of the primary carcinoma leading to a higher R0
resection (i.e. resection with microscopic tumour clearance at
resection margins) rate and a reduction of subsequent local
recurrence; surgical resection of the primary tumour; and post-
operative adjuvant chemotherapy to eliminate residual micrometa-
stasis especially in those with R1 resection (microscopic incomplete
resection with tumour present p1mm of the resection margin).
During neoadjuvant and adjuvant chemotherapy, a combination
of mitomycin C (MMC) and protracted venous infusion (PVI)
5-fluorouracil (5-FU) was used in our study based on the in vitro
synergy of these two drugs (Russello et al, 1989) and a superior
response rate, failure-free survival and quality of life for this
combination compared with PVI 5-FU alone in a previous
randomised study of 200 patients with advanced colorectal cancer
(Ross et al, 1997). Preoperative MMC, infused 5-FU/leucovorin
and radiotherapy have also been shown to be an effective
treatment for tethered/fixed rectal cancers (Chan et al, 2000).
The objectives of this study were to evaluate the feasibility and
benefits of delivering neoadjuvant chemotherapy prior to syn-
chronous chemoradiation and surgery in patients with newly
diagnosed locally advanced rectal cancer.
PATIENTS AND METHODS
This study was approved by the local biomedical ethics committee.
Signed, written informed consent was obtained from each patient.
Patients selection and evaluation
The eligibility criteria were: locally advanced histologically proven
adenocarcinoma of rectum; no previous chemotherapy or radio-
therapy; no evidence of metastatic disease on clinical examination
and radiological imaging; bidimensionally measurable disease;
haemoglobin 410gdl
 1, white blood count 43 10
9l
 1,n e u t r o -
phil 41.5 10
9l
 1,p l a t e l e t4100 10
9l
 1, bilirubin o30mmoll
 1,
creatinine o180mmoll
 1 and calculated creatinine clearance
460mlmin
 1.
Before entry into the study, all patients were assessed by our
cancer network multi-disciplinary team comprising medical,
radiation and surgical oncologists, gastroenterologists and radi-
ologists. Patients were considered to have locally advanced disease
on the basis of digital rectal examination and imaging (computed
tomography (CT) or magnetic resonance imaging (MRI)). All
patients had at least T3N0 disease on pretreatment clinical staging.
All patients were required to have chest X-ray (CXR), CT scan of
chest, abdomen and pelvis and carcinoembryonic antigen (CEA)
measurement.
MRI scans of the pelvis were performed as previously described
(Brown et al, 1999) in patients who could tolerate the procedure
and had no contraindications to MRI, but were not mandated in
the protocol because of inaccessibility to urgent staging MRI from
some referring clinicians at the beginning of the study. However,
MRI scans were obtained in the majority of enrolled patients. MRI
criteria for locally advanced disease were: tumour extending to
within 1mm of or beyond the mesorectal fascia (i.e. CRM involved
or threatened); T3 low-lying tumour at or below the levators,
tumour extending 5mm or more into perirectal fat, T4 tumours
and T1-4N2 tumours. Information from both imaging and digital
rectal examination was considered complimentary to give final
staging.
Treatment
Figure 1 shows the overall treatment schema.
Neoadjuvant chemotherapy Twelve weeks of neoadjuvant chemo-
therapy was given. Mitomycin C (7mgm
 2) was delivered as a
bolus injection repeated every 6 weeks, thus, a total of two doses
were given during this period. Screening of the peripheral blood
film for red cell fragmentation, indicating a risk of developing
haemolytic uraemic syndrome with further MMC therapy, was
mandated before each course of MMC. A maximum dose of 14mg
of MMC was allowed in each course. 5-FU (300mgm
 2day
 1) was
administered as a continuous infusion via a central venous
catheter (Hickman line). No routine antiemetic medications were
given. Warfarin (1mgday
 1 orally) was administered throughout
the treatment to prevent catheter thrombosis.
Dose modifications Toxicity was assessed according to National
Cancer Institute–Common Toxicity Criteria (NCI–CTC) version 2
(1998). Toxicity data were collected weekly during chemotherapy.
If grade 3 and 4 neutropenia occurred, subsequent doses of MMC
were reduced by 25 and 50%, respectively. If stomatitis, hand–foot
syndrome or diarrhoea relating to 5-FU developed, 50, 100 and
150mgm
 2 dose reductions in 5-FU were made if grade 2, 3 and 4
toxicities developed, respectively.
Synchronous chemoradiation (CRT) On completion of 12 weeks’
neoadjuvant chemotherapy, patients began chemoradiation. This
was delivered by a two-phase technique, both phases were CT
planned and involved the use of customised blocking on all fields.
Phase 1 delivered a total of 45Gy in 25 daily fractions, each of
CT± MRI scans at 12 weeks and after radiotherapy to reassess operability 
PVI 5-FU
300 mg m−2 day−1
300 mg m−2 day −1
0
Weeks
6 12 18 +6
weeks
+12
weeks
RT 45 Gy in 25# phase 1
5.4−9 Gy phase 2
PVI 5-FU200 mg m−2 day−1
PVI 5-FU
after recovery from
surgery
MMC
7 mg m−2
MMC
7 mg m−2
MMC
7 mg m−2
MMC
7 mg m−2
4−6 weeks rest for recovery of
acute RT toxicity then SURGERY
MMC = Mitomycin C, PVI 5-FU = Protracted venous infusion of 5-FU, RT = Radiotherapy.
Figure 1 Treatment schema.
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pelvic lymph nodes. The superior margin was at the level of L5/S1
while the inferior margin varied depending on the position of the
tumour within the rectum, but with a minimum of 3cm margin on
the inferior extent. Laterally, the pelvic side walls, plus 1cm, were
covered and the sacrum was included posteriorly. The anterior
margin depended on the position and extent of the tumour. During
phase 2, the protocol aim was to deliver 9Gy in five fractions
covering the tumour either clinically palpable or visible on
imaging with a 2cm margin in all directions. Where CT planning
indicated that small bowel could not be adequately excluded from
this volume, the dose was modified to 5.4Gy in three fractions. The
information used to define the phase 2 target was the pretreatment
CT scan, pretreatment clinical evaluation and, where available,
pretreatment MRI.
Both the phase 1 and 2 were delivered by three field techniques,
a posterior and two laterals or two lateral obliques. Patients were
treated prone with a full bladder and received concomitant PVI 5-
FU at a reduced dose of 200mgm
 2day
 1 throughout radio-
therapy. If patients already had dose reduction of 5-FU to below
200mgm
 2day
 1 during neoadjuvant chemotherapy, that same
reduced dose of 5-FU would be applied during synchronous
chemoradiation.
Dose modifications Acute toxicity was assessed according to
Radiation Therapy Oncology Group–Acute Radiation Morbidity
Scoring Criteria. Toxicity data were collected weekly during
radiotherapy and then 1 month after radiotherapy. If toxicity
because of 5-FU occurred during CRT, the dose was adjusted as
outlined in the neoadjuvant chemotherapy section.
Surgery Surgery was performed 6 weeks after the completion of
CRT. The choice of surgical procedure (abdomino-perineal
resection or anterior resection) was at the surgeons’ discretion.
Postoperative adjuvant chemotherapy An identical 12 week block
of postoperative chemotherapy, consisting of MMC and PVI 5-FU
at the same preoperative doses, was given to all patients who had
recovered within 12 weeks of surgery and had no evidence of
distant disease postoperatively.
Evaluation of response
Clinical tumour response was measured using CT and MRI scans.
CT scans were repeated after the initial neoadjuvant chemotherapy
at 12 weeks, after synchronous chemoradiation at 22 weeks
(i.e. 4 weeks after finishing RT) and before commencement of
postoperative adjuvant chemotherapy. The primary intention of
CT scan was to exclude any development of distant metastasis.
MRI scans of pelvis were repeated once after synchronous
chemoradiation to assess primary tumour response. All available
imaging was reviewed independently by one radiologist (GB), who
was blinded to the pathological findings. The local T and N stage
and tumour measurement were made according to previously
published criteria (Brown et al, 1999). No confirmatory scans for
responses were performed.
Radiological tumour response was evaluated according to World
Health Organisation (WHO) Criteria (Miller et al, 1981). Complete
response (CR) was defined as the complete disappearance of all
measurable lesions, without the appearance of new lesion(s).
Partial response (PR) was defined as a reduction of bidimensional
lesions by X50% of the sum of the products of the largest
perpendicular diameters of each measurable lesion and no
progression in other lesions or the appearance of any new lesions.
Stable disease (SD) was defined as a o50% reduction of tumour
volume or a o25% increase of the volume of one or more
measurable lesions, with no new lesions. Progressive disease (PD)
was defined as an increase of X25% of the size of at least one
bidimensionally measurable lesion, the appearance of new
lesion(s), and/or the onset of ascites or pleural effusion with
cytological confirmation.
During neoadjuvant chemotherapy, tumour-related symptoms
were assessed by research nurses with a 15-point checklist at
baseline and at each hospital visit for patients who had these
symptoms on entry into study. Particular enquiry was made
regarding symptoms of rectal bleeding, pelvic pain/tenesmus and
diarrhoea/constipation. Disappearance or attenuation of these
tumour-related symptoms were recorded at each hospital visit.
Data regarding the time between commencement of treatment and
resolution of symptoms were collected weekly. This symptom
checklist has been used in a number of previous multicentre
randomised studies (Ross et al, 1997, 2002; Cunningham et al,
1998; Maisey et al, 2002; Tebbutt et al, 2002).
Pathological response was assessed by examining the resected
tumour specimen after chemoradiation and compared with
baseline clinical staging using imaging and digital rectal examina-
tion. The American Joint Committee on Cancer TNM staging
system (fifth edition) was used when assessing for pathological
response. Tumour downstaging was defined as a reduction of at
least one level in T or N staging (e.g. T3 to T2, N2 to N0). Tumour
specimens were also examined for resection margin involvement.
CRM involvement was defined as tumour observed p1mm from
the resection margin.
Follow-up
Patients were seen in the routine follow-up clinic every 3 months
for the first year, every 6 months for the second year and then
annually. CEA measurement was performed with each clinic visit.
CT scans of thorax, abdomen and pelvis were performed 1 year
and 2 years after the end of treatment.
Statistical analysis
Failure-free survival and overall survival were estimated using the
Kaplan–Meier method from trial entry (Kaplan and Meier, 1958).
All end points were updated in May, 2002. Failure-free survival was
calculated from the date chemotherapy commenced to the date of
either disease progression or death. Overall survival was estimated
from the date chemotherapy commenced to the date of death from
any cause.
RESULTS
In all, 36 eligible patients were recruited between January 1999 and
August 2001. The median follow-up for these patients is 15
months. Table 1 shows the patient demographics. At baseline, both
MRI and CT scan were carried out in 30 patients and CT scans
alone were performed in six patients. Table 2 shows the baseline
clinical staging. One patient had T3N1 rectal cancer on initial MRI
report and was enrolled into the trial, but was subsequently
reclassified as T2N0 after radiology review. This patient was
included in all analyses. Eleven patients had the potential
mesorectal CRM threatened or involved by tumour on MRI at
baseline. Of those, CRM was threatened by nodal or extranodal
tumour deposits rather than by primary tumour directly in five
patients.
Figure 2 shows the progress of all patients during the trial. No
patient developed detectable progressive disease after neoadjuvant
chemotherapy. In two patients, liver metastases were evident on
CT after synchronous chemoradiation. No progression in primary
tumours was seen during the trial.
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Radiological response All 36 patients were evaluable for radi-
ological response (Table 3). CT scans were performed on all 36
patients after neoadjuvant chemotherapy and synchronous CRT.
Pelvic MRI scans were performed in 32 patients only after CRT.
Four patients did not have post-CRT MRI scans because of patient
refusal (n¼2), in situ coronary stent (n¼1) and unavailability of
MRI (n¼1).
After neoadjuvant chemotherapy, the best achieved objective
response rate (ORR) of all patients were 27.8% (95% confidence
interval [CI]: 14.2–45.2%) with one CR and nine PRs. After
chemoradiation, the objective response rate was 80.6% (95% CI:
64–91.8%) with six CRs and 23 PRs.
Resolution of symptoms Overall 65% of patients had an
improvement or resolution of symptoms. Of the patients with
symptoms, 59% had improvement in diarrhoea/constipation, 60%
had reduced rectal bleeding and 78% had diminished pelvic pain
and tenesmus. All symptomatic improvement was evident during
neoadjuvant chemotherapy. The median time to improvement in
diarrhoea/constipation was 28 days (interquartile range¼7–43
days) and for diminished pelvic pain and tenesmus was 35 days
(interquartile range¼7.5–56 days).
Surgery and pathological response Nineteen patients underwent
an anterior resection and 15 had an abdomino-perineal resection.
Patients proceeded to surgery in a median of 6.9 weeks after
finishing RT. One patient with T4N1 tumour was found to be still
inoperable at laparotomy and no attempt of surgical resection was
made. One 85-year-old patient achieved a clinical complete
response on both imaging and sigmoidoscopic evaluation and
declined surgery after CRT. He developed local recurrence 14
months later and underwent a successful TME with complete
tumour clearance. Both patients who developed liver metastases
after CRT opted to undergo resection of primary tumour before
receiving further palliative chemotherapy. One patient was found
to have metastases on the serosal surface of liver at operation
undetected on preoperative CT. Thus, potentially curative surgery
was attempted on 33 patients. Another patient was found to have a
rise in CEA level during the postoperative recovery period. A
positron emission tomography (PET) scan demonstrated wide-
spread metastatic disease without evidence of active disease on
postoperative CT.
Compared with baseline staging, 25 patients (73.5%) had down-
staging of their primary tumour on histological examination either
in T (n¼13) or N (n¼7) or both (n¼5) staging. Pathological CR
was found in one patient. Table 4 shows the pathological response in
patients who underwent resection of their primary tumour. The
median number of lymph nodes retrieved in the surgical specimens
was 5 (range 0–17). In one patient only, no lymph nodes were
identified (Nx) from the surgical specimen after CRT.
Table 1 Patient characteristics
Patient characteristics Number of patients (total n=36)
Gender
Male 26
Female 10
Median age
(range)
63 years
(40–85)
Performance status
01 3
12 3
One patient
inoperable
19 patients
had anterior
resection
36 eligible
patients
finished 1st
block of chemo-
therapy
36 patients
finished
chemo
radiation
36 patients
considered
for surgery
Two patients had
PD postchemo
radiation*
No patients
had PD
postchemo-
therapy One patient had
clinical CR
and declined
surgery
15 patients
had AP
resection
PD = Progressive disease, CR = complete response, AP resection = abdomino-perineal resection.
*Both patients proceeded to surgery despite development of liver metastasis after chemoradiation.
Figure 2 Progress of all patients during trial.
Table 2 Baseline staging using CT7MRI scans and digital rectal
examination
Baseline
staging
Number of
patients (%) n=36
Number of patients
with CRM involved
or threatened by
tumour n=11
T2N0
a 1 (2.8) 0
T3N0 6 (16.7) 1
T3N1 8 (22.2) 2
T3N2 6 (16.7) 6
T4N0 8 (22.2) 2
T4N1 5 (13.9) 0
T4N2 2 (5.6) 0
CRM=circumferential resection margin.
aT3N1 on initial MRI reporting at trial entry, but subsequently reclassified after
radiology review.
Table 3 Objective tumour responses by imaging
Post
chemotherapy
(CT only)
Post
chemoradiation
(CT7MRI)
Complete response 1 (2.8%) 6 (16.7%)
Partial response 9 (25%) 23 (63.9%)
Stable disease 26 (72.2%) 5 (13.9%)
Progressive disease 0 (0%) 2 (5.6%)
Objective response rates
(95% confidence interval)
27.8% (14.2–45.2%) 80.6% (64–91.8%)
Table 4 Pathological response
Pathological staging
Baseline
staging pT0 pT1 pT2 pT3 pT4
T2 0 0 1 0 0
T3 0 3 4 11 1
T4 1 0 2 8 3
pNode negative pNode positive
Node negative 12 2
Node positive 8 12
Neoadjuvant chemotherapy in rectal cancer
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the 11 patients with threatened or involved CRM on baseline MRI
scan, nine had tumour regression from the resection margin after
CRT. In only one patient, tumour was predicted to have regressed
from CRM on postCRT MRI, but histology showed involved
resection margin.
Postoperative adjuvant chemotherapy
Twenty-two patients (61%) received adjuvant chemotherapy.
Fourteen patients did not receive adjuvant chemotherapy because
of postoperative complications (n¼5), progressive disease or
inoperable tumour (n¼5) and physicians’ or patients’ decision
(n¼4). One patient developed venous thrombosis secondary to
Hickman line and received capecitabine instead of PVI 5-FU
during adjuvant chemotherapy.
Toxicity
Neoadjuvant chemotherapy-induced toxicity Table 5 shows the
incidences of grade 3/4 toxicities during neoadjuvant chemother-
apy. There were no deaths related to chemotherapy. No grade 3/4
haematological toxicity was seen. Nine patients (25%) developed
grade 3/4 nonhaematological toxicity although only 3% were grade
4. The most common nonhaematological toxicity was hand–foot
syndrome.
Chemoradiation-induced toxicity Table 5 shows the incidences of
grade 3/4 toxicities during chemoradiation. There were no deaths
related to chemoradiation either. The most frequent toxic effect
was treatment field erythema. In most cases, this had resolved
when patients were reviewed one month after completion of
radiotherapy. No haematological, lower gastrointestinal and
genitourinary grade 3/4 toxicities were encountered during
chemoradiation. No treatment interruption was required.
Surgical complications One patient died postoperatively from an
anastamotic leak leading to multiorgan failure. No other anasta-
motic leak was seen. Five other patients developed postoperative
complications including pelvic collections (n¼3) and delayed
wound healing (n¼2).
Survival
Six out of 36 patients (16.7%) have died. Cause of death was
progressive cancer in all cases. The median survival has not yet
been reached (Figure 3). The survival probability at 1 year was
93.5% (95% CI: 76.3–98.4%) and at 2 years was 70.3% (95% CI:
42.3–86.6%).
Patterns of failure
The median failure-free survival was 18.6 months (Figure 4). The
failure-free survival probability at 1 year was 72.1% (95% CI: 52.9–
84.5%). Two patients had local recurrences, nine developed distant
metastasis (lung n¼3, liver n¼4, brain n¼1 and paraaortic
lymphadenopathy n¼1) and one had both local and distant
disease as their first sites of treatment failure.
DISCUSSION
In this study, we assessed the feasibility of delivering neoadjuvant
chemotherapy before preoperative CRT and radical resection. This
treatment strategy potentially addresses systemic micrometastases
as well as reduces the frequency of locoregional recurrence. A
reduction in the size of the primary tumour with neoadjuvant
chemotherapy may have improved the effectiveness of chemo-
radiotherapy and also increased R0 resection rate. This is
supported by the fact that 41% of patients included in our study
had T4 tumours and a further 33% had tumour extending to the
potential mesorectal CRM in whom resection with curative intent
would not normally be attempted. Of these patients, 77%
underwent a R0 resection. Moreover, neoadjuvant chemotherapy
resulted in rapid symptom resolution which would impact on
patients’ quality of life. Antitumour treatment could also be started
in a timely fashion without potential delay as long course radical
Table 5 Treatment induced grade 3/4 toxicity
Toxicity Number of patients
During neoadjuvant chemotherapy
Anaemia 0 (0%)
Neutropenia 0 (0%)
Thrombocytopenia 0 (0%)
Diarrhoea 3 (8.3%)
Stomatitis 1 (2.8%)
Hand–foot syndrome 4 (11%)
Infection 2 (5.6%)
Febrile neutropenia 0 (0%)
During chemoradiation
Anaemia 0 (0%)
Neutropenia 0 (0%)
Thrombocytopenia 0 (0%)
Lower gastrointestinal 0 (0%)
Genitourinary 0 (0%)
Skin 10 (27.8%)
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Kingdom.
Several strategies have been used to reduce either local
recurrence or distant metastasis for localised rectal cancer.
Improved surgical technique such as total mesorectal excision
has been reported to have a lower local recurrence rate and
improved survival compared to conventional surgery (Havenga
et al, 1999; Kapiteijn et al, 2002). The value of preoperative RT in
operable rectal cancer has been evaluated in two meta-analyses
(Camma et al, 2000; Colorectal Cancer Collaborative Group, 2001).
Whereas the Colorectal Cancer Collaborative Group, using
individual data from 6350 patients enrolled in 13 randomised
studies, found a marginal but nonsignificant survival advantage in
patients receiving preoperative RT (Colorectal Cancer Collabora-
tive Group, 2001), a significant reduction in mortality was found
by the meta-analysis undertaken by Camma et al (2000). Both
meta-analyses demonstrated a significant reduction in local
recurrence with preoperative RT. The role of preoperative RT
was further examined in the Dutch TME trial in which the surgical
technique was standardised (Kapiteijn et al, 2001). Although no
significant difference in 5-year survival was seen between the two
arms, the local recurrence rate in the preoperative RT group
(5.8%) was significantly lower than in the surgery alone group
(11.6%) (Van de Velde, 2002).
At least three randomised studies of preoperative vs post-
operative chemoradiation have been conducted, but the two
studies from the US (INT-0147 and NSABP R-03) closed
prematurely because of poor accrual. In the National Surgical
Adjuvant Breast and Bowel Project (NSABP) R-03 trial with only
267 patients randomised, a larger proportion of patients receiving
preoperative treatment had sphincter saving surgery (44 vs 34%)
and had no evidence of disease at 1 year compared to those
receiving postoperative treatment (Roh et al, 2001). However,
increased toxicity and a slight increase in early deaths were seen in
the preoperative arm. The German CAO/ARO/AIO-94 study
showed that preoperative chemoradiation was well tolerated and
carried no higher risk of postoperative morbidity, but efficacy data
are awaited (Sauer et al, 2001).
Although many studies evaluated the use of preoperative
chemoradiation in patients with newly diagnosed locally advanced
rectal cancer, the definition of locally advanced disease varies
between studies (Glimelius, 2001). Many recent studies included
T3 tumours staged by endoscopic ultrasound which are often less
bulky than clinically staged T3 tumours. Very few patients with T4
tumours were recruited (o5% of total enrolled) in these studies
(Janjan et al, 1999; Bosset et al, 2000; Chan et al, 2000; Grann et al,
2001; Onaitis et al, 2001; Valentini et al, 2001). In our study, over
40% of patients had T4 tumours representing a group of patients
with truly locally advanced disease. This may account for the low
pathological complete response rate seen in our study compared
with 10–30% achieved in other studies (Janjan et al, 1999; Bosset
et al, 2000; Chan et al, 2000; Grann et al, 2001; Onaitis et al, 2001;
Valentini et al, 2001). Two studies included only patients with
clinically staged T4 tumours (Videtic et al, 1998; Rodel et al, 2000).
The pathological CR rate was lower (Rodel et al, 2000) and R0
resection was less frequently achieved (Videtic et al, 1998)
compared to other published studies despite the use of higher
dose radiotherapy. Toxicity was significant in one study with 16%
not completing protocol (Rodel et al, 2000). Patients with T or N
downstaging have been shown to have a significantly improved
local control, freedom from distant metastasis, disease-free
survival and overall survival (Valentini et al, 2002). Despite a
low pCR rate, our pathological downstaging rate of 74% would be
clinically meaningful to this group of patients with advanced
disease.
In our study, the radiological tumour response rate was 28%
after neoadjuvant chemotherapy increasing to 81% after chemo-
radiation. Although the radiation component would have con-
tributed to the greatly improved response rate after chemoradia-
tion, it is conceivable that CT imaging, that was used primarily to
exclude distant spread after neoadjuvant chemo-therapy, might
have underestimated the primary tumour response compared to
MRI that was used after chemoradiation. A clinical response after
preoperative CRT in rectal cancer has been shown to predict
significantly better long-term clinical outcomes (Valentini et al,
2002). This supports the use of preoperative tumour assessment
by imaging rather than simply relying on pathological downstaging
as an efficacy outcome measure. However, the accuracy of MRI in
the assessment of the primary rectal cancer after chemotherapy
or chemoradiation has not been examined extensively. Continuing
evaluation of MRI, positron emission tomography and endoscopic
ultrasound after neoadjuvant treatment as a guide to surgical
management may allow more conservative approach for respond-
ing patients. However as noted in our study and other studies
(Hiotis et al, 2002), many patients with clinical CR had persistent
foci of tumours that were not detectable on preoperative imaging,
therefore treatment decisions should not be based solely on
the absence of clinically palpable or visible tumour after
chemoradiation. Indeed, one patient with clinical CR in our study
was found to have residual tumour and CRM involvement
following resection highlighting the risk of no excision after
obtaining a clinical CR.
The ability of MRI to accurately stage rectal cancer (Brown et al,
1999; Beets-Tan et al, 2001), define the potential mesorectal
circumferential margin (Brown et al, 1999) and predict CRM
involvement (Beets-Tan et al, 2001) has been demonstrated before
and supported its use in the initial staging of patients in our study.
Encouragingly, over 80% of patients in our study with CRM
threatened or involved initially demonstrated tumour regression
from the CRM after treatment, thus allowing a greater proportion
of curative surgery to be performed. Reassuringly, the prediction
of CRM involvement after treatment by MRI was relatively
accurate in our study and might be used to guide surgical
management after neoadjuvant treatment in the future. Other MRI
features such as tumour thickness, tumour appearances, extra-
mural spread may give complimentary information about tumour
response in addition to TNM staging. An analysis of MRI features
at baseline and postchemoradiation and their correlation with
pathological findings and survival for patients undergoing a
similar treatment programme in our institution has been
performed and will be reported separately. An ongoing study in
Europe (MERCURY, Magnetic Resonance Imaging and Rectal
Cancer European Equivalence Study) is designed to correlate MRI
findings on extramural spread and potential CRM involvement
with pathological specimen and will provide valuable information
on the use of MRI for rectal cancer.
Direct comparison of our efficacy results with other studies
would be problematic because of differences in the patient
population (e.g. proportion of patients with T4 or node-positive
tumours), and in the doses and schedules of drugs used in the
preoperative CRT. The follow-up in our study is also relatively
short to assess the impact of our treatment programme on
survival. Rather, we have demonstrated the feasibility of using
neoadjuvant chemotherapy prior to synchronous CRT, and the
immediate benefits associated with its use such as tumour
response, resolution of symptoms, low risk of disease progression
and R0 resectability in many patients.
Neoadjuvant chemotherapy with MM C and PVI 5-FU was
well tolerated with no unexpected toxicity, the incidence of side
effects was similar to that reported in randomised studies (Ross
et al, 1997; Maisey et al, 2002; Tebbutt et al, 2002) and it also did
not increase the frequency of severe adverse events during CRT.
The low incidence of grade 3/4 lower gastrointestinal and
genitourinary toxicity during CRT might be related to the fact
that patients underwent 12 weeks of neoadjuvant chemotherapy
prior to CRT, therefore patients who were susceptible to
Neoadjuvant chemotherapy in rectal cancer
I Chau et al
1022
British Journal of Cancer (2003) 88(7), 1017–1024 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lfluorouracil-related toxicity would have had appropriate dose
reductions already.
However, our strategy will require further refinement. A more
effective approach would be incorporation of newer chemotherapy
agents as distant metastasis is the most frequent cause of our
treatment failures. Oxaliplatin and infused 5-FU/leucovorin (LV)
has shown considerable antitumour activity in randomised phase
III studies (de Gramont et al, 2000; Giacchetti et al, 2000) and has
recently been found to be superior to irinotecan/bolus 5-FU/LV in
terms of efficacy and toxicity profile in metastatic colorectal cancer
(Goldberg et al, 2002). Concomitant oxaliplatin, infused 5-FU/ LV
and radiotherapy have been reported in locally advanced rectal
cancer with a pathological complete response rates of 14–29%
(Freyer et al, 2001; Aschele et al, 2002; Gerard et al, 2002; Sebag-
Montefiore et al, 2002). Capecitabine has also been combined
with oxaliplatin (Borner et al, 2002; Taberno et al, 2002) or
radiotherapy (Dunst et al, 2002; Kim et al, 2002) and yielded
promising activity in colorectal cancer. In our current active
protocol, we have elected to substitute MMC and PVI 5-FU with
oxaliplatin and capecitabine during the neoadjuvant chemotherapy
and use capecitabine as the radiosensitising agent during
chemoradiation.
In conclusion, neoadjuvant systemic chemotherapy prior to
synchronous chemoradiation can be administered with negligible
risk of local disease progression and low risk of systemic spread. It
produced considerable symptomatic response with associated
tumour regression. This treatment programme allowed sufficient
tumour shrinkage for R0 resection in the majority of our patients
with locally advanced rectal cancer including those with initial
circumferential resection margin involvement.
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